ArticleNPJ precision oncology2023

Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy.

Zechen Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.